GRAIL stock
GRALNASDAQGRAIL Inc., HealthcareISIN US3847471014
43Score 43 out of 100, Weak
Price and trend
81 / 100
Price history
+43% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 53% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 24% below its 52-week high. Largest decline in 2 years: 63% (January 2026 to February 2026).
Chart figures for advanced users
- SMA 50$120.73
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$79.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$43.03
- The lowest closing price of the last twelve months.
- Resistance$158.92
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GRAIL Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $5.46B, is number 23 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $147.17M (up 17.2% year on year) and a loss of $408.35M.
- For fiscal 2026, analysts expect on average revenue of $178.19M (up 21.1%) and adjusted earnings per share of −$9.49.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 486 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $788.68M, financial debt $85.85M.Stability 69
Weaknesses
- Volatile share priceVolatility 102% a year over the last 12 months.Stability 69
- Loss-makingLoss of $406.18M over the last 12 months.Fundamentals 17
- DilutionShare count up 18% since 2021.Capital allocation 18
Its standout strengths are technical analysis and momentum, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17.5% on the twelve months before. Revenue turned from negative at the start of the period to positive ($147.17M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −43%, operating −363%, net −277%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 18 Feb 2027in 97 days
- Last reported
- 4 Nov 2026EPS reported −$2.21 (expected −$2.56)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$9.49+1.4%
- Revenue
- $178.19M−1.5%
- Earnings per share
- −$10.13+1.4%
- Revenue
- $222.55M−1.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −12.8%Expectation unchanged: the FDA is expected to convene an advisory committee in the fall, with a decision expected in early 2027.
“As Galleri is a first-of-its-kind technology and multi-cancer early detection represents a potential paradigm shift in cancer screening, we do expect the FDA to convene an advisory committee for Galleri in the fall.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $14.92M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Ofman Joshua J.Sale
15 Oct 2026, Chief Executive Officer
- Shares
- 20,000
- Price
- $136.85
- Value
- $2.74M
- Partridge Andrew JohnSale
5 Oct 2026, Chief Growth Officer
- Shares
- 7,873
- Price
- $146.39
- Value
- $1.15M
- Freidin AaronSale
5 Oct 2026, Chief Financial Officer
- Shares
- 23,619
- Price
- $146.39
- Value
- $3.46M
Show 5 more
- Freidin AaronSale
21 Sept 2026, Chief Financial Officer
- Shares
- 4,100
- Price
- $93.34
- Value
- $382,679
- Ofman Joshua J.Sale
21 Sept 2026, Chief Executive Officer
- Shares
- 61,452
- Price
- $97.74
- Value
- $6.01M
- Ofman Joshua J.Sale
27 Aug 2026, Chief Executive Officer
- Shares
- 5,000
- Price
- $85.02
- Value
- $425,098
- Freidin AaronSale
27 Aug 2026, Chief Financial Officer
- Shares
- 7,900
- Price
- $85.01
- Value
- $671,579
- Partridge Andrew JohnSale
4 Jun 2026, Chief Growth Officer
- Shares
- 1,491
- Price
- $61.08
- Value
- $91,070
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at GRAIL
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- bioMérieuxBIM.PA $12.04B70
- WuXi XDC Cayman2268.HK $11.58B74
- QiagenQGEN $10.35B75
- RadNetRDNT $5.98B44
- DiaSorinDIA.MI $5.3B67
- BillionToOneBLLN $5.29B64
- Sotera HealthSHC $4.65B54
- CareDxCDNA $4.19B59
ETFs that hold GRAIL
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 2.51% | 0.49% | €318.64M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.47% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.35% | 0.35% | €1.25B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.27% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.18% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.17% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.07% | 0.43% | €2.5B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.05% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 13 Jun 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.